LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Last trade$76.35
Day change-$0.66 (-0.86%)
Day range$76.05 – $77.52
Volume78,432
Market cap$1.76B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.76B
Price / earnings
27.82×
Price / book
4.08×
Price / sales
6.54×
EV / sales
7.07×
EV / EBITDA
22.27×
Profitability
Earnings per share
$2.77
Return on assets
9.65%
Return on equity
14.66%
Dividend yield
1.23%
Liquidity and leverage
Debt / equity
0.39×
Current ratio
14.6×
Quick ratio
12.54×
Cash ratio
0.79×
Cash flow
Price / cash flow
23.12×
Price / free cash flow
26.3×
Free cash flow
$67M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LMAT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$67.97M
$70.38M
$66.55M
$64.45M
$61.05M
$64.23M
$59.87M
$55.72M
Cost of revenue
$19.27M
$19.62M
$18.16M
$18.26M
$15.09M
$19.26M
$18.45M
$17.13M
Gross profit
$48.71M
$50.76M
$48.4M
$46.19M
$45.96M
$44.97M
$41.42M
$38.59M
Selling, general and administrative
$26.59M
$25.52M
$26.56M
$23.83M
$22.67M
$25.29M
$24.7M
$22.12M
Research and development
$4.42M
$4.85M
$4.06M
$3.53M
$2.97M
$3.54M
$4.1M
$3.62M
Total operating expenses
$31.01M
$30.37M
$30.62M
$27.36M
$25.64M
$28.83M
$28.79M
$25.74M
Operating income
$17.7M
$20.4M
$17.78M
$18.83M
$20.31M
$16.14M
$12.63M
$12.85M
Interest expense
-$1.3M
-$1.3M
-$1.3M
-$1.3M
-$1.3M
-$1.3M
-$1.29M
-$205K
Income before taxes
$19.67M
$22.19M
$19.67M
$20.3M
$22.57M
$18.07M
$14.24M
$14.02M
Income taxes
$4.65M
$5.14M
$3.99M
$4.72M
$5.21M
$4.29M
$3.23M
$2.84M
Net income
$15.02M
$17.05M
$15.68M
$15.58M
$17.36M
$13.78M
$11.01M
$11.18M
Net income attributable to common shareholders
$15.02M
$17.05M
$15.68M
$15.58M
$17.36M
$13.78M
$11.01M
$11.18M
EBITDA
$20.58M
$23.06M
$20.4M
$21.44M
$22.93M
$18.79M
$15.18M
$15.27M
Basic earnings per share
$0.66
$0.75
$0.69
$0.69
$0.77
$0.61
$0.49
$0.50
Diluted earnings per share
$0.65
$0.74
$0.68
$0.72
$0.75
$0.60
$0.48
$0.49
Recent news
Company coverage with links to the original publishers.
LeMaitre Vascular, Inc. announced it will release its third quarter 2026 financial results on November 4, 2026, after market close, followed by a conference call at 5:00 PM EST to discuss results, business highlights, and company outlook.
In a comparison of two Medical-Products sector stocks, Phibro Animal Health (PAHC) emerges as the superior value investment option compared to LeMaitre Vascular (LMAT). PAHC holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 11.20 and PEG ratio of 1.13. LMAT, rated #4 (Sell) with a Value grade of D, has a forward P/E of 28.10 and PEG ratio of 2.34, indicating it is relatively overvalued.
LeMaitre Vascular reported Q1 2026 sales of $66.6mm (+11% organic growth) with gross margin expanding 350 bps to 72.7% and EPS growing 42% to $0.68. The company raised full-year 2026 guidance to $280mm sales (+12%) and $3.00 EPS (+26% adjusted). Strong performance was driven by Artegraft growth of 36%, geographic expansion, and operating leverage. The board approved a $0.25/share quarterly dividend and authorized a $100mm share repurchase program.
LeMaitre Vascular's Senior VP of Operations sold $285,000 in stock (2,625 shares) on March 11, 2026, representing 28.22% of his direct holdings. The sale appears to be a routine option-driven liquidity event rather than a red flag, as the company reported strong Q4 results with 16% sales growth, 47% operating income increase, raised its dividend by 25%, and initiated a $100 million buyback program. The stock has surged 30% over the past year driven by improved margins and consistent demand.
LeMaitre Vascular announced its participation in five investor conferences scheduled for March 2026, including presentations at the Leerink Partners Global Healthcare Conference, Citizens Life Sciences Conference, and KeyBanc Capital Markets Healthcare Forum, as well as 1x1 meetings at the Barclays Annual Global Healthcare Conference and ROTH Conference.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.25 per share
Declared
Oct 27, 2026
Ex-dividend
Nov 19, 2026
Pay date
Dec 3, 2026
Ex-dividend
Amount / share
Pay date
Type
Aug 20, 2026
$0.25
Sep 3, 2026
recurring
May 21, 2026
$0.25
Jun 4, 2026
recurring
Mar 12, 2026
$0.25
Mar 26, 2026
recurring
Nov 20, 2025
$0.20
Dec 4, 2025
recurring
Aug 21, 2025
$0.20
Sep 4, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.